Captrust Financial Advisors Raises Holdings in Amgen Inc. (NASDAQ:AMGN)

Captrust Financial Advisors raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 2.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 583,626 shares of the medical research company’s stock after acquiring an additional 14,253 shares during the quarter. Captrust Financial Advisors’ holdings in Amgen were worth $188,050,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in AMGN. Capital Performance Advisors LLP purchased a new position in Amgen in the 3rd quarter valued at approximately $25,000. Strategic Financial Concepts LLC purchased a new position in shares of Amgen in the second quarter valued at $26,000. Hershey Financial Advisers LLC purchased a new position in shares of Amgen in the second quarter valued at $30,000. nVerses Capital LLC acquired a new position in shares of Amgen during the 2nd quarter worth $31,000. Finally, Bbjs Financial Advisors LLC purchased a new stake in shares of Amgen in the 2nd quarter worth about $33,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Truist Financial downgraded shares of Amgen from a “buy” rating to a “hold” rating and raised their target price for the company from $320.00 to $333.00 in a report on Monday, October 14th. StockNews.com cut shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Thursday. William Blair restated an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Redburn Partners lowered their target price on Amgen from $200.00 to $195.00 in a report on Wednesday. Finally, Sanford C. Bernstein started coverage on Amgen in a research report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price objective on the stock. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Amgen currently has an average rating of “Hold” and an average target price of $323.05.

Amgen Stock Performance

NASDAQ:AMGN opened at $280.07 on Friday. The firm’s fifty day simple moving average is $312.46 and its 200 day simple moving average is $317.31. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. Amgen Inc. has a twelve month low of $257.80 and a twelve month high of $346.85. The firm has a market capitalization of $150.55 billion, a price-to-earnings ratio of 35.86, a PEG ratio of 2.50 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same period last year, the company posted $4.96 earnings per share. The firm’s revenue was up 23.2% compared to the same quarter last year. As a group, equities research analysts expect that Amgen Inc. will post 19.52 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be issued a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 3.21%. The ex-dividend date is Monday, November 18th. Amgen’s dividend payout ratio is presently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.